The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Inhaled Iloprost for Severe Pulmonary Hypertension
Open accessAbstract
BACKGROUND: Uncontrolled studies suggested that aerosolized iloprost, a stable analogue of prostacyclin, causes selective pulmonary vasodilatation and improves hemodynamics and exercise capacity in patients with pulmonary hypertension. METHODS: We compared repeated daily inhalations of 2.5 or 5.0 microg of iloprost (six or nine times per day; median inhaled dose, 30 microg per day) with inhalation of placebo. A total of 203 patients with selected forms of severe pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (New York Heart Association [NYHA] functional class III or IV) were included. The primary end point was met if, after week 12, the NYHA class and distance walked in six minutes were improved by at least one class and at least 10 percent, respectively, in the absence of clinical deterioration according to predefined criteria and death. RESULTS: The combined clinical end point was met by 16.8 percent of the patients receiving iloprost, as compared with 4.9 percent of the patients receiving placebo (P=0.007). There were increases in the distance walked in six minutes of 36.4 m in the iloprost group as a whole (P=0.004) and of 58.8 m in the subgroup of patients with primary pulmonary hypertension. Overall, 4.0 percent of patients in the iloprost group (including one who died) and 13.7 percent of those in the placebo group (including four who died) did not complete the study (P=0.024); the most common reason for withdrawal was clinical deterioration. As compared with base-line values, hemodynamic values were significantly improved at 12 weeks when measured after iloprost inhalation (P<0.001), were largely unchanged when measured before iloprost inhalation, and were significantly worse in the placebo group. Further significant beneficial effects of iloprost treatment included an improvement in the NYHA class (P=0.03), dyspnea (P=0.015), and quality of life (P=0.026). Syncope occurred with similar frequency in the two groups but was more frequently rated as serious in the iloprost group, although this adverse effect was not associated with clinical deterioration. CONCLUSIONS: Inhaled iloprost is an effective therapy for patients with severe pulmonary hypertension.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1992) · PubMed · Cited by 33,716
The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
Statistical Aspects of the Analysis of Data From Retrospective Studies of Disease
(1959) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/22.4.719 · Cited by 14,689
Bosentan Therapy for Pulmonary Arterial Hypertension
Rubin, L. J., Badesch, D. B., Barst, R. J., Galiè, N., Black, C. M., Keogh, A., Pulido, T., Frost, A., Roux, S., Leconte, I., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012212 · Cited by 2,726
Self-citationBarst, R. J., Rubin, L. J., Long, W. A., McGoon, M. D., Rich, S., Badesch, D. B., Groves, B. M., Tapson, V. F., Bourge, R. C., Brundage, B. H., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602013340504 · Cited by 2,698
Self-citationThe 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure.
Guyatt, G. H., Sullivan, M. J., Thompson, P. J., Fallen, E. L., Pugsley, S. O., Taylor, D. W., & Berman, L. (1985) · Europe PMC (PubMed Central) · Cited by 2,401
SIMONNEAU, G., BARST, R. J., GALIE, N., NAEIJE, R., RICH, S., BOURGE, R. C., KEOGH, A., OUDIZ, R., FROST, A., BLACKBURN, S. D., et al. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.6.2106079 · Cited by 1,441
Self-citationMahler, D. A., Weinberg, D. H., Wells, C. K., & Feinstein, A. R. (1984) · Chest · doi:10.1378/chest.85.6.751 · Cited by 1,292
Badesch, D. B., Tapson, V. F., McGoon, M. D., Brundage, B. H., Rubin, L. J., Wigley, F. M., Rich, S., Barst, R. J., Barrett, P. S., Kral, K. M., et al. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-6-200003210-00002 · Cited by 1,075
Self-citationMcLaughlin, V. V., Genthner, D. E., Panella, M. M., & Rich, S. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380501 · Cited by 664
Galiè, N., Humbert, M., Vachiéry, J.-L., Vizza, C., Kneussl, M., Manes, A., Sitbon, O., Torbicki, A., Delcroix, M., Naeije, R., et al. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)01786-2 · Cited by 648
Self-citationHoeper, M. M., Schwarze, M., Ehlerding, S., Adler-Schuermeyer, A., Spiekerkoetter, E., Niedermeyer, J., Hamm, M., & Fabel, H. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006223422503 · Cited by 572
Self-citationSurvival in Primary Pulmonary Hypertension with Long-Term Continuous Intravenous Prostacyclin
Barst, R. J., Rubin, L. J., McGoon, M. D., Caldwell, E. J., Long, W. A., & Levy, P. S. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-121-6-199409150-00003 · Cited by 551
Self-citationInhaled Prostacyclin and Iloprost in Severe Pulmonary Hypertension Secondary to Lung Fibrosis
OLSCHEWSKI, H., ARDESCHIR GHOFRANI, H., WALMRATH, D., SCHERMULY, R., TEMMESFELD-WOLLBRÜCK, B., GRIMMINGER, F., & SEEGER, W. (1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.160.2.9810008 · Cited by 410
Self-citationWalmrath, D., Schneider, T., Schermuly, R., Olschewski, H., Grimminger, F., & Seeger, W. (1996) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.153.3.8630585 · Cited by 331
Self-citationHoeper, M. M., Olschewski, H., Ghofrani, H. A., Wilkens, H., Winkler, J., Borst, M. M., Niedermeyer, J., Fabel, H., & Seeger, W. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(99)00494-5 · Cited by 313
Self-citationInhaled Iloprost To Treat Severe Pulmonary Hypertension: An Uncontrolled Trial
Olschewski, H., Ghofrani, H. A., Schmehl, T., Winkler, J., Wilkens, H., Hoeper, M. M., Behr, J., Kleber, F. X., Seeger, W., & for the German PPH Study Group* (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-6-200003210-00003 · Cited by 286
Self-citationAerosolised prostacyclin in adult respiratory distress syndrome
WALMRATH, D., Schneider, T. L., Pilch, J., Grimminger, F., & Seeger, W. (1993) · The Lancet · doi:10.1016/0140-6736(93)92004-d · Cited by 284
Self-citationInhaled prostacyclin (PGI2) versus inhaled nitric oxide in adult respiratory distress syndrome.
Zwissler, B., Kemming, G., Habler, O., Kleen, M., Merkel, M., Haller, M., Briegel, J., Welte, M., & Peter, K. (1996) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.154.6.8970353 · Cited by 249
Rebound pulmonary hypertension on withdrawal from inhaled nitric oxide
Miller, O. I., Tang, S. F., Keech, A., & Celermajer, D. S. (1995) · The Lancet · doi:10.1016/s0140-6736(95)92681-x · Cited by 199
Effects of Aerosolized Prostacyclin in Severe Pneumonia. Impact of Fibrosis
WALMRATH, D., Schneider, T., Pilch, J., SCHERMULY, R. T., Grimminger, F., & Seeger, W. (1995) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.151.3.7881662 · Cited by 123
Self-citationLife‐threatening effects of discontinuing inhaled nitric oxide in children
Cueto, E., López‐Herce, J., Sánchez-Galindo, A., & Carrillo, A. (1997) · Acta Paediatrica · doi:10.1111/j.1651-2227.1997.tb14909.x · Cited by 63
Caution with use of inhaled nitric oxide
Warren, J., & Higenbottam, T. (1996) · The Lancet · doi:10.1016/s0140-6736(05)65068-4 · Cited by 61
Self-citation
Cited by
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Galiè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv317 · Cited by 6,931
Self-citation2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Humbert, M., Kovacs, G., Hoeper, M. M., Badagliacca, R., Berger, R. M. F., Brida, M., Carlsen, J., Coats, A. J. S., Escribano-Subias, P., Ferrari, P., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac237 · Cited by 3,975
Self-citationAuthors/Task Force Members, Galie, N., Hoeper, M. M., Humbert, M., Torbicki, A., Vachiery, J.-L., Barbera, J. A., Beghetti, M., Corris, P., Gaine, S., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp297 · Cited by 3,846
Self-citationGaliè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2015) · European Respiratory Journal · doi:10.1183/13993003.01032-2015 · Cited by 3,172
Self-citationSildenafil Citrate Therapy for Pulmonary Arterial Hypertension
Galiè, N., Ghofrani, H. A., Torbicki, A., Barst, R. J., Rubin, L. J., Badesch, D., Fleming, T., Parpia, T., Burgess, G., Branzi, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050010 · Cited by 2,476
Self-citation
Metadata
- Authors
- Olschewski, H., Simonneau, G., Galiè, N., Higenbottam, T., Naeije, R., Rubin, L. J., Nikkho, S., Speich, R., Hoeper, M. M., Behr, J., Winkler, J., Sitbon, O., Popov, W., Ghofrani, H. A., Manes, A., Kiely, D. G., Ewert, R., Meyer, A., Corris, P. A., Delcroix, M., Gomez-Sanchez, M., Siedentop, H., & Seeger, W.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-08
- Volume
- 347
- Issue
- 5
- Pages
- 322-329
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2090213540
- Cited by
- 1,783
- References
- 24
- FWCI
- 69.89
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.